Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3084] to Fibrinogen gamma chain
- Suitable for: WB, IHC-P
- Reacts with: Human
Product nameAnti-Fibrinogen gamma chain antibody [EPR3084]
See all Fibrinogen gamma chain primary antibodies
DescriptionRabbit monoclonal [EPR3084] to Fibrinogen gamma chain
Tested applicationsSuitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or IP
Species reactivityReacts with: Human
Synthetic peptide corresponding to residues in Human Fibrinogen gamma chain (UniProt ID: P02679).
- WB: Human plasma lysate IHC-P: Human liver tissue
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab92481 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/500 - 1/1000. Predicted molecular weight: 52 kDa.
Is unsuitable for Flow Cyt or IP.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGG are a cause of thrombophilia.
Defects in FGG are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. It is a rare autosomal recessive disorder characterized by complete absence of detectable fibrinogen.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsConversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Sulfation of C-terminal tyrosines increases affinity for thrombin.
- Information by UniProt
- FGG antibody
- FIBG_HUMAN antibody
- Fibrinogen gamma chain antibody
Anti-Fibrinogen gamma chain antibody [EPR3084] (ab92481) at 1/500 dilution + Human
plasma lysate at 10 µg
HRP labelled goat anti-rabbit IgG at 1/2000 dilution
Predicted band size: 52 kDa
ab92481, at a 1/100 dilution, staining Fibrinogen gamma chain in paraffin embedded Human liver tissue by Immunohistochemistry.
Heat mediated antigen retrieval was performed before commencing with IHC staining protocol.
ab92481 has not yet been referenced specifically in any publications.